



National Headquarters

March 26, 2002

Dear Healthcare Provider,

**Subject: Thrombotic Events and Immune Globulin Intravenous (IGIV)**

There are many articles that describe the occurrence of thrombotic events in patients receiving immune globulin intravenous (1-28\*). In view of the serious nature of these reported thrombotic events, we wish to draw your attention to the product insert for Polygam® S/D, which includes a statement to this effect under the 'Precautions' section of the document. The precautionary statement is as follows:

*There is clinical evidence of a possible association between Immune Globulin Intravenous (Human) (IGIV) administration and thrombotic events. The exact cause of this is unknown; therefore, caution should be exercised in the prescribing and infusion of IGIV in patients with a history of cardiovascular disease or thrombotic episodes.*

From both the medical literature and our internal pharmacovigilance/quality assurance program, we continue to receive reports describing serious thrombotic (vascular occlusive) events possibly associated with the infusion of immune globulin intravenous (IGIV). Analysis of these events indicates that the etiology is complex and the cause of this association is not clearly understood.

However, our own recent analysis of serious adverse events reported via pharmacovigilance, has identified rapid infusion of immune globulin intravenous as a possible risk factor. Grillo and co-workers also report on the use of rapid infusion of immune globulin intravenous in patients with neuromuscular disorders in the November 2001 issue of the journal *Neurology*, Vol. 57 (pages 1699 – 1701). Their abstract and discussion claim safety and convenience of this practice in their population of patients and the final sentence of their abstract states "Rapid infusion IVIg can be given safely and conveniently in many patients with neuromuscular disorders." While this is accurate for the majority of their patients, the authors report 89 adverse events in 341 rapid infusions in 50 patients, 3.5% of which were considered "major." This amounted to a "major" event in 11 out of 50 patients (22%).

It is these "major" events, and their frequency, which are of concern to us as these events included chest pain, myocardial infarction, congestive cardiac failure, severe headache requiring hospitalization, and pulmonary embolism. These are serious events almost

certainly directly related to the rapid infusion protocol (reaching as high as 800 ml/hour) in what is essentially an at-risk population.

The American Red Cross is stressing that our IGIV products should be administered only as stipulated by the package insert. We further recommend that all patients with thrombotic risk factors such as coronary artery disease, hypertension, cerebrovascular disease, diabetes mellitus, in whom IGIV is an appropriate therapeutic agent be carefully evaluated, and the infusion concentration for these patients should be no more than 5%. The infusion rate should be initiated no faster than 0.5 milliliter per kilogram body weight per hour and **increased slowly** only if well tolerated to a maximum rate of 4 milliliter per kilogram body weight per hour. In other words, the rate of infusion and percent of the solution concentration should be flexible and targeted to the safety of the patient rather than convenience.

**It is strongly recommended that clinicians and other health care workers such as pharmacists and nurses who may be associated with the therapeutic administration of immune globulin intravenous, read and follow the product insert. We ask that you share this information with those individuals responsible for administering IGIV therapy.**

Please refer to the enclosed product direction insert for more complete prescribing information. If you have any further questions or concerns regarding this letter, please call American Red Cross Medical Affairs at (800) 293-5023.

Sincerely,

A handwritten signature in dark ink, appearing to read "Fred Darr", followed by a horizontal line.

Fred Darr, MD  
Director, Medical Affairs  
American Red Cross

\* **References**

1. Woodruff RK, Grigg AP, Firkin FC, Smith IL: Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. *Lancet* **2(8500)**: 217-218, 1986
2. Frame WD, and Crawford RJ: Thrombotic Events after Intravenous Immunoglobulin. *Lancet* **2(8504)**: 468, 1986
3. Comenzo RL, Malachowski ME, Meissner HC, Fulton DR, Berkman EM: Immune hemolysis, disseminated intravascular coagulation, and serum sickness after large doses of immune globulin given intravenously for Kawasaki disease. *Journal of Pediatrics* **120(6)**: 926-928, 1992
4. Reinhart WH, Berchtold PE: Effect of high-dose intravenous immunoglobulin therapy on blood rheology. *Lancet* **339(8794)**: 662-664, 1992
5. Silbert PL, Knezevic WV, Bridge DT: Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis. *Neurology* **42(1)**: 257-258, 1992
6. Madl C, Koppensteiner R, Wendelin B, Lenz K, Kramer L, Grimm G, Kranz A, Schneeweiss B, Ehringer H: Effect of Immunoglobulin Administration on Blood Rheology in Patients with Septic Shock. *Circulatory Shock* **40(4)**: 264-267, 1993
7. Durand JM, Lefevre P, Kaplanski G, Retornaz F, Cretel E, Soubeyrand J: Deleterious Effects of Intravenous Immunoglobulin in a Patient with Thrombotic Thrombocytopenic Purpura. *American Journal of Hematology* **44(3)**: 214-215, 1993
8. Steg RE, Lefkowitz DM. Cerebral infarction following intravenous immunoglobulin therapy for myasthenia gravis. *Neurology* **44(6)**: 1180-1181, 1994
9. Dalakas MC: High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. *Neurology* **44(2)**: 223-226, 1994
10. Duhem C, Dicato MA, Ries F: Side effects of intravenous immune globulins. *Clinical & Experimental Immunology* **97 (Suppl 1)**: 79-83, 1994
11. Harkness K, Howell SJ, Davies-Jones GA: Encephalopathy associated with intravenous immunoglobulin treatment for Guillain-Barre syndrome. *Journal of Neurology, Neurosurgery, Psychiatry* **60(5)**: 586, 1996
12. Hashkes PJ, Lovell DJ: Vasculitis in systemic lupus erythematosus following intravenous immunoglobulin therapy. *Clinical & Experimental Rheumatology* **14(6)**: 673-675, 1996

13. Brannagan TH 3rd, Nagle KJ, Lange DJ, Rowland LP: Complications of intravenous immune globulin treatment in neurologic disease. *Neurology* **47**(3): 674-677, 1996
14. Bertorini TE, Nance AM, Horner LH, Greene W, Gelfand MS, Jaster JH: Complications of Intravenous Gammaglobulin in Neuromuscular and other diseases. *Muscle & Nerve* **19**(3): 388-391, 1996
15. Oh KT, Boldt HC, Danis RP: Iatrogenic central retinal vein occlusion and hyperviscosity associated with high-dose intravenous immunoglobulin administration. *American Journal of Ophthalmology* **124** (3): 416-418, 1997
16. Fisman DN, Smilovitch M: Intravenous Immunoglobulin, Blood Viscosity and Myocardial Infarction. *Canadian Journal of Cardiology* **13**(8): 775-777, 1997
17. Rosenbaum JT: Myocardial Infarction as a complication of immunoglobulin therapy. *Arthritis Rheumatology* **40**(9): 1732-1733, 1997
18. Stangel M, Hartung HP, Marx P, Gold R: Review: Side effects of High-Dose Intravenous Immunoglobulins. *Clinical Neuropharmacology* **20**(5): 385-393, 1997
19. Haplea SS, Farrar JT, Gibson GA, Laskin M, Pizzi LT, Ashbury AK: Thromboembolic Events Associated with Intravenous Immunoglobulin Therapy: *Neurology* **48**: A54, 1997
20. Chatot-Henry C, Smadja D, Mehdaoui H, Fournier P, Drault JN, Brebion A, Sobesky G: Acute renal insufficiency and cerebral infarction during high-dose intravenous immunoglobulin therapy.(French) *Revue de Medecine Interne* **19** (12): 914-916, 1998
21. Sztajzel R, Le Floch-Rohr J, Eggimann P: High-Dose Intravenous Immunoglobulin Treatment and Cerebral Vasospasm: A Possible Mechanism of Ischemic Encephalopathy? *Journal of European Neurology* **41**(3): 153-158 1999.
22. Kwan T, and Keith P: Stroke Following Intravenous Immunoglobulin Infusion in a 28-Year-Old Male with Common Variable Immune Deficiency: A Case Report and Literature Review. *Canadian Journal of Allergy & Clinical Immunology* **4**: 250-253, 1999
23. Go RS, Call TG: Deep Venous Thrombosis of the Arm After Intravenous Immunoglobulin Infusion: Case Report and Literature Review of Intravenous Immunoglobulins-Related Thrombotic Complications. *Mayo Clinical Proceedings* **75**(1): 83-85, 2000

24. Elkayam O, Paran D, Milo R, Davidovitz Y, Almozni-Sarafian D, Zelster D, Yaron M, Caspi D: Acute Myocardial Infarction Associated with High Dose Intravenous Immunoglobulin Infusion for Autoimmune Disorders. A study of four cases. *Annals of Rheumatic Diseases* **59(1)**: 77-80, 2000
25. Paolini R, Fabris F, Cella G: Acute myocardial infarction during treatment with intravenous immunoglobulin for idiopathic thrombocytopenic purpura (ITP). *American Journal of Hematology* **65(2)**: 177-178, 2000
26. Alliot C, Rapin JP, Besson M, Bedjaoui F, Messouak D: Pulmonary embolism after intravenous immunoglobulin. *Journal of the Royal Society of Medicine* **94(4)**: 187-188, 2001
27. Grillo JA, Gorson KC, Ropper AH, Lewis J, Weinstein R: Rapid infusion of intravenous immune globulin in patients with neuromuscular disorders. *Neurology* **57(9)**: 1699-1701, 2001
28. Gomperts ED, Darr F: Letter to the Editor: Reference article - Rapid infusion of intravenous immune globulin in patients with neuromuscular disorders. *Neurology*, 2002. In Press